Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696129 | 0.77 | ADORA1 (0.66) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL4985489 | 0.77 | ADORA1 (0.55) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL5498164 | 0.76 | ADORA1 (0.55) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL4985196 | 0.75 | ADORA1 (0.55) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL4990200 | 0.74 | ADORA1 (0.62) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL4986845 | 0.74 | ADORA1 (0.69) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL3068195 | 0.74 | ADORA2B (0.64) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL787601 | 0.74 | ADORA2B (0.64) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL8874884 | 0.74 | ADORA1 (0.76) | ADORA1ADORA3ADORA2BADORA2AMEN1 | |
| SCHEMBL8836301 | 0.74 | ADORA1 (0.76) | ADORA1ADORA3ADORA2BADORA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | claimed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885ADORA3 6/4885ADORA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.